Keymed Biosciences annonce l’approbation accordée au Stapokibart pour le traitement de la rhinite allergique saisonnière

Posted on by

CHENGDU, Chine, 10 février 2025 /PRNewswire/ — Keymed Biosciences (HKEX : 02162) a annoncé aujourd’hui que la National Medical Products Administration (la « NMPA ») de Chine a récemment approuvé la demande supplémentaire de nouveau médicament (la « sNDA ») pour le Stapokibart (anticorps…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.